Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number.

NCT ID: NCT05854589

Last Updated: 2023-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effectiveness of applying Hypertonic Saline solution directly on the Melanomas in reducing their sizes and/or number.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many previous studies have shown that Cancer cells are over-hydrated, and that Hyponatraemia exists in many cases of Cancer. The Cancer cell's viability depends on Angiogenesis and formation of blood vessels that carry water and nutrients to the rapidly-dividing Cancer cells. This study tests the hypothesis that reducing the water content of Melanoma could lead to increasing its tonicity and hence inhibiting its growth. This reduction of water content can be achieved using Osmotic Pressure differential via applying highly saline solution - made by Sodium Chloride crystals wet with water - directly on the Melanoma for a certain amount of time, thus leading to water withdrawal from Melanoma cells. While the surrounding healthy skin cells can sustain temporary dehydration, Melanoma cells could be negatively affected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma (Skin)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A pilot randomized controlled study, whereas a number of patients with clinically-diagnosed skin Melanoma (any location and any stage), and who were poorly responsive to at least one cycle of conventional and standard therapy, are equally divided into 2 groups, Active and Control groups. Each patient of the Active group will have their Melanoma covered by 2 drops of water, followed by applying Sodium Chloride granules to saturate the melanoma surface then add 2 more drops of water, then cover the NaCl-granules-covered Melanoma with a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any. Each patient of the Control group will undergo the same treatment as the Active group patients minus the Sodium Chloride granules.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Group - Sodium Chloride Crystal Topical

Each patient of the Active group will have their Melanoma covered by 2 drops of water, followed by applying Sodium Chloride granules to saturate the melanoma surface then add 2 more drops of water, then cover the NaCl-granules-covered Melanoma with a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.

Group Type ACTIVE_COMPARATOR

Sodium Chloride Granules

Intervention Type DRUG

Sodium Chloride crystals

Control Group - Plain Water topical application

Each patient of the Control group will have their Melanoma covered by 4 drops of water, then covered by a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any.

Group Type PLACEBO_COMPARATOR

Water

Intervention Type OTHER

Plain distilled water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium Chloride Granules

Sodium Chloride crystals

Intervention Type DRUG

Water

Plain distilled water

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with clinically-confirmed Melanoma (any location and any stage) who have poorly responded to at least one cycle of conventional and standard therapy (Chemotherapy, Radiation or Drug therapy).
* Age 5 to 80 years old
* Life expectancy of at least 1 year
* Can understand and read English
* Lives in USA.

Exclusion Criteria

* Skin eczema and/or other skin conditions contraindicated to skin dehydration.
* Ulcers or open wounds close to Melanoma
* Any medical condition that might cause the patient to lose consciousness
* Participants who are not residents of USA.
Minimum Eligible Age

5 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rafik Batroussy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rafik Batroussy

Registered Pharmacist, Director

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rafik Batroussy, BPharm

Role: STUDY_CHAIR

Independent Researcher

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rafik Batroussy, BPharm

Role: CONTACT

1-403-796-4441

References

Explore related publications, articles, or registry entries linked to this study.

McIntyre GI. Cell hydration as the primary factor in carcinogenesis: A unifying concept. Med Hypotheses. 2006;66(3):518-26. doi: 10.1016/j.mehy.2005.09.022. Epub 2005 Nov 3.

Reference Type BACKGROUND
PMID: 16271440 (View on PubMed)

Machado M, Salgado TM, Hadgraft J, Lane ME. The relationship between transepidermal water loss and skin permeability. Int J Pharm. 2010 Jan 15;384(1-2):73-7. doi: 10.1016/j.ijpharm.2009.09.044. Epub 2009 Sep 30.

Reference Type BACKGROUND
PMID: 19799976 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.nature.com/articles/nchem.2021

Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells.

https://www.frontiersin.org/articles/10.3389/fimmu.2019.01141/full

High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity.

http://royalsocietypublishing.org/doi/abs/10.1098/rspb.1932.0065

The osmotic passage of water and gases through the human skin.

https://www.nature.com/articles/s41567-019-0680-8

Cell swelling, softening and invasion in a three-dimensional breast cancer model.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment Use Study for Advanced Melanoma.
NCT00584493 NO_LONGER_AVAILABLE